Evidence map›Paper›PMID 21632071›Full record

ArticleMetabolism: clinical and experimental2011

Deletion of interleukin-6 improves pyruvate tolerance without altering hepatic insulin signaling in the leptin receptor-deficient mouse.

Alicia H Clementi, Allison M Gaudy, Teresa A Zimmers, Leonidas G Koniaris, Robert A Mooney

Open access · greenAbstract read
In one paragraph

Article in Metabolism: clinical and experimental, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Impaired Glucose Homeostasis in a Tau Knock-In Mouse Model.Frontiers in molecular neuroscience · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alicia H ClementiDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.
Allison M Gaudy
Teresa A Zimmers
Leonidas G Koniaris
Robert A Mooney
University of Miami · USUniversity of Rochester Medical Center · US

Funding

Manipulation of STAT3 Signaling for Muscle Preservation in Cancer CachexiaR01CA122596 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ZIMMERS, TERESA A · 2010 to 2015
$1.6M
Myostatin Family Signaling in Burn-Injury Related Muscle WastingR01GM092758 · NIGMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ZIMMERS, TERESA A · 2010 to 2014
$1.6M
SOCS Proteins - Inhibitors of Hepatic Insulin ReceptorsR01DK060732 · NIDDK · UNIVERSITY OF ROCHESTER · PI MOONEY, ROBERT A · 2003 to 2006
$1.2M
NCI NIH HHS R01 CA122596NIDDK NIH HHS R01 DK060732NIDDK NIH HHS R01-DK060732NIGMS NIH HHS R01 GM092758
6 · The paper itself

Abstract

Obesity is associated with increased circulating interleukin-6 (IL-6), which may contribute to hepatic insulin resistance by impairing insulin receptor signaling. This study was designed to assess the impact of the systemic absence of IL-6 on the development of insulin resistance and glucose intolerance in an obese mouse model. Systemic insulin, glucose, and pyruvate tolerance tests were performed in IL-6 knockout (IL6KO) mice that had been crossed with a genetically obese (leptin receptor-deficient mouse model [Lep(db)]) mouse model. Real-time reverse transcriptase polymerase chain reaction and Western blot analysis assessed cellular and molecular markers of insulin signaling, inflammation, and metabolism. Absence of IL-6 did not improve systemic glucose or insulin tolerance, but Lep(db) × IL6KO mice displayed a smaller blood glucose increase following a pyruvate challenge. These results suggest that loss of IL-6 in the context of obesity may locally reduce hepatic glucose production from a gluconeogenic precursor. Hepatic insulin-dependent insulin receptor autophosphorylation, Akt activation, and FoxO1 phosphorylation were similar between Lep(db) × IL6KO mice and Lep(db) controls. Basal gene expression of the gluconeogenic enzyme phosphoenolpyruvate carboxykinase was reduced in male Lep(db) × IL6KO mice relative to Lep(db) controls; but gene expression of another regulatory enzyme, glucose-6-phosphatase, remained unaltered. Absence of IL-6 reduced gene expression of serum amyloid A and RelA in female Lep(db) mice, but did not alter hepatic triglyceride accumulation or lipogenic gene expression. Overall, our results suggest that IL-6 may be detrimental in obesity by contributing to elevated hepatic glucose output.

Indexed as

AnimalsDrug ResistanceFemaleGene DeletionInsulin ResistanceInterleukin-6LiverMaleMiceMice, Inbred C57BLMice, KnockoutPyruvic AcidReceptors, LeptinSignal TransductionInterleukin-6leptin receptor, mousePyruvic AcidReceptors, Leptin

Identifiers

PMID21632071
PMCPMC3166542
OpenAlexW2079657677

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.